Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

Cancer Chemotherapy and Pharmacology
J HortiI Bodrogi

Abstract

The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1,027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks. Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) <or=2; adequate organ function; and age >or=20 and <75 years. The patients were administered TZT-1,027 in escalating doses from 0.5 to 5.6 mg/m(2). Pharmacokinetic samples were collected during each treatment course. Forty-nine patients were enrolled. Three patients had DLTs, including neutropenia, neutropenia complicated by fever, myalgia, and neuropathic pain. The common toxicities included constipation, anorexia, alopecia, nausea, leukopenia, and neutropenia. One complete response and three partial responses were observed. The pharmacokinetic parameters (AUC and C (max)) of TZT-1,027 tended to increase linearly with dose. DLTs included neutropenia, neutropenia complicated by fever, myalgia, ...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Oct 1, 1995·Chemical & Pharmaceutical Bulletin·K MiyazakiS Tsukagoshi
Mar 1, 1997·Japanese Journal of Cancer Research : Gann·M KobayashiS Tsukagoshi
Apr 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L M KrugM G Kris
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Aug 2, 2000·Japanese Journal of Cancer Research : Gann·T NatsumeM Kobayashi
Aug 31, 2000·Japanese Journal of Cancer Research : Gann·M OtaniT Nakayama
Mar 3, 2001·Apoptosis : an International Journal on Programmed Cell Death·J WatanabeM Kobayashi
Oct 24, 2002·American Journal of Clinical Oncology·Everardo D SaadJames L Abbruzzese
Apr 16, 2003·Gynecologic Oncology·Mark A HoffmanUNKNOWN Gynecologic Oncology Group Study
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maja J A de JongeJaap Verweij
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 1, 2005·Investigational New Drugs·Hedy L KindlerEverett E Vokes
Sep 27, 2006·Cancer Science·Junichi WatanabeMotohiro Kobayashi

❮ Previous
Next ❯

Citations

Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Mar 14, 2012·Current Opinion in Oncology·Antoine HollebecqueJean-Charles Soria
Feb 10, 2010·Expert Opinion on Investigational Drugs·Si-Meng ChenJian Ding
Oct 21, 2015·Analytical Cellular Pathology (Amsterdam)·Daniele FanaleViviana Bazan
May 30, 2013·Surgical Neurology International·Emory McTyrePrakash Chinnaiyan
Feb 12, 2020·Biomolecules·Edina WangAnabel Sorolla
Jul 5, 2017·Clinical and Experimental Pharmacology & Physiology·Haibo XingDa Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.